基本信息:
- 专利标题： HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
- 专利标题（中）：人抗PD-1，PD-L1和PD-L2抗体及其用途
- 申请号：PCT/US2009058475 申请日：2009-09-25
- 公开(公告)号：WO2010036959A2 公开(公告)日：2010-04-01
- 发明人： FREEMAN GORDON , AHMED RAFI , JONES TIMOTHY D , CARR FRANCIS J , GREGSON JAMES P
- 申请人： DANA FARBER CANCER INST INC , UNIV EMORY , FREEMAN GORDON , AHMED RAFI , JONES TIMOTHY D , CARR FRANCIS J , GREGSON JAMES P
- 专利权人： DANA FARBER CANCER INST INC,UNIV EMORY,FREEMAN GORDON,AHMED RAFI,JONES TIMOTHY D,CARR FRANCIS J,GREGSON JAMES P
- 当前专利权人： DANA FARBER CANCER INST INC,UNIV EMORY,FREEMAN GORDON,AHMED RAFI,JONES TIMOTHY D,CARR FRANCIS J,GREGSON JAMES P
- 优先权： US10053408 2008-09-26
- 主分类号： C07K16/18
- IPC分类号： C07K16/18 ; A61K39/395 ; A61P31/00 ; A61P35/00
摘要：
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
摘要（中）：
本发明部分基于新型人抗PD-1，PD-L1和PD-L2抗体的鉴定。 因此，本发明涉及用于诊断，预后和治疗将受益于调节PD-1，PD-L1和/或PD-L2活性（例如持续感染性疾病，自身免疫性疾病，哮喘，移植物）的病症的组合物和方法 排斥，炎性疾病和肿瘤），使用本文所述的新的人抗PD-1，PD-L1和PD-L2抗体。
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07K | 肽 |
| ------C07K16/00 | 免疫球蛋白，例如，单克隆或多克隆抗体 |
| --------C07K16/18 | .来自动物或人的抵抗物质 |